As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many
paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK …

Childhood cancer is considered rare, corresponding to~ 3% of all malignant neoplasms in
the human population. The World Health Organization (WHO) reports a universal …

Overall survival from childhood malignancies has dramatically improved, with survival rates
now reaching over 70%. Nevertheless, some types of childhood cancer remain a difficult …

Among mammalian mitogen-activated protein kinase (MAPK) signaling cascades, the
extracellular signal-related kinase (ERK) pathway has received the most attention in the …

DNA damage response inhibitors have a potentially important therapeutic role in paediatric
cancers; however, their optimal use, including patient selection and combination strategy …

Introduction Regulatory decisions on paediatric investigation plans (PIPs) aim at making
effective and safe medicines timely available for children with high unmet medical need. At …

An urgent need remains for new paediatric oncology drugs to cure children who die from
cancer and to reduce drug-related sequelae in survivors. In 2007, the European Paediatric …

Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving
survival and reducing long-term side-effects for children and adolescents with cancer. The …

Seven years after the launch of the European Paediatric Medicine Regulation, limited
progress in paediatric oncology drug development remains a major concern amongst …

Well-designed and carefully conducted pediatric phase I trials are critical to the process of
evaluating new agents for potential benefit in children with cancer, and the National Cancer …